Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalizing bladder treatment: could your other pills determine which drug works best?

NCT ID NCT07711808

Disease control Sponsor: Universidade do Porto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study compares two common medications for overactive bladder (OAB): solifenacin, which blocks nerve signals in the bladder, and mirabegron, which helps the bladder muscle relax. Researchers want to see if a person's 'anticholinergic burden'—the combined effect of other medications that also block those nerve signals—affects how well each drug works. Adults with newly diagnosed OAB who have not yet been treated will take one of the two drugs for two months, and their symptom improvement will be tracked.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
solifenacin or mirabegron
What this could lead to
If successful, this study could help doctors choose the most effective first-line OAB treatment based on a person's existing medications, improving symptom relief and quality of life.
What could go wrong
This is a relatively small, short-term study (2 months) and results may not apply to everyone. The findings depend on accurate measurement of anticholinergic burden, which can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 208 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients with a clinical diagnosis of overactive bladder syndrome. * Treatment-naïve for OAB pharmacotherapy (no prior antimuscarinic or mirabegron for OAB). * Able to complete the ICIQ-OAB questionnaire and a frequency-volume chart. * Written informed consent. Exclusion Criteria: * Neurogenic bladder. * Previous treatment with anticholinergics or mirabegron for OAB. * History of pelvic radiotherapy or bladder cancer. * Post-void residual volume \> 200 mL. * Clinically significant stress urinary incontinence. * Chronic pelvic pain syndrome. * Congenital urinary tract malformations. * Prior bladder surgery; history of mid-urethral sling or prostate surgery. * Contraindication to solifenacin or mirabegron. * End-stage renal disease on dialysis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Overactive bladder (OAB) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

overactive bladder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Overactive bladder (OAB)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.